These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8643898)

  • 1. [Therapy of low-grade non-Hodgkin lymphomas].
    Hiddemann W; Unterhalt M; Wörmann B
    Praxis (Bern 1994); 1996 Mar; 85(12):357-63. PubMed ID: 8643898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Low-grade malignant non-Hodgkin lymphomas--current status and trends in therapy].
    Hiddemann W
    Ther Umsch; 1996 Feb; 53(2):123-32. PubMed ID: 8629262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status and future perspectives in the treatment of low-grade non-Hodgkin's lymphomas.
    Hiddemann W; Unterhalt M
    Blood Rev; 1994 Dec; 8(4):225-33. PubMed ID: 7888829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy of low-grade non-Hodgkin's lymphoma].
    Heinz R; Hopfinger-Limberger G
    Wien Klin Wochenschr; 1994; 106(10):321-6. PubMed ID: 8053200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
    Zinzani PL; Martelli M; Poletti V; Vitolo U; Gobbi PG; Chisesi T; Barosi G; Ferreri AJ; Marchetti M; Pimpinelli N; Tura S; ; ;
    Haematologica; 2008 Sep; 93(9):1364-71. PubMed ID: 18603558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
    Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF
    Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Systemic therapy of low malignancy non-Hodgkin lymphomas].
    Wörmann B; Buske C; Hiddemann W
    Praxis (Bern 1994); 1998 Jun; 87(23):806-11. PubMed ID: 9654987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment results of tonsillar lymphoma: a 10-year experience.
    Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
    Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary intestinal lymphoma: clinical and therapeutic features of 32 patients.
    Zinzani PL; Magagnoli M; Pagliani G; Bendandi M; Gherlinzoni F; Merla E; Salvucci M; Tura S
    Haematologica; 1997; 82(3):305-8. PubMed ID: 9234576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medicinal therapy of malignant lymphomas].
    Aul C; Schroeder M; Giagounidis A
    Radiologe; 2002 Dec; 42(12):943-53. PubMed ID: 12486548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Hodgkin's lymphomas--current status of therapy and future perspectives.
    Hiddemann W
    Eur J Cancer; 1995 Dec; 31A(13-14):2141-5. PubMed ID: 8652232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
    Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
    Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of follicular follicle centre lymphomas: current status and future perspectives.
    Hiddemann W; Unterhalt M; Buske C; Sack H
    J Intern Med Suppl; 1997; 740():55-62. PubMed ID: 9350184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index.
    Fanin R; Silvestri F; Geromin A; Infanti L; Sperotto A; Cerno M; Stocchi R; Savignano C; Rinaldi C; Damiani D; Baccarani M
    Bone Marrow Transplant; 1998 Feb; 21(3):263-71. PubMed ID: 9489649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy.
    Hausdorff J; Davis E; Long G; Hoppe R; van der Pas M; Lassman C; Kamel O; Jacobs C
    Cancer J Sci Am; 1997; 3(5):303-11. PubMed ID: 9327155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.